Market capitalization | $11.85m |
Enterprise Value | $27.61m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.75 |
P/S ratio (TTM) P/S ratio | 0.75 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 16.98% |
Revenue (TTM) Revenue | $15.77m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Eiger BioPharmaceuticals, Inc.:
1 Analyst has issued a forecast Eiger BioPharmaceuticals, Inc.:
Dec '23 |
+/-
%
|
||
Revenue | 16 16 |
17%
17%
|
|
Gross Profit | 15 15 |
39%
39%
|
|
EBITDA | -71 -71 |
23%
23%
|
EBIT (Operating Income) EBIT | -72 -72 |
23%
23%
|
Net Profit | -75 -75 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | David Apelian |
Employees | 25 |
Founded | 2008 |
Website | www.eigerbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.